What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the first quarter of 2025 and to furnish the associated press release as an exhibit.

What are non-GAAP financial measures and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) results. Abbott uses them to provide investors with a clearer view of ongoing business performance by removing the impact of unusual or unpredictable items, such as acquisition-related costs, restructuring actions, and intangible amortization.

What specific items are excluded in Abbott's non-GAAP financial measures?

Abbott's non-GAAP financial measures typically exclude expenses related to acquisitions, restructuring actions, fair value adjustments to contingent consideration, impairment charges, certain regulatory costs, specific tax-related adjustments (including prior year resolutions and excess tax benefits from stock compensation), and intangible amortization expense.

How should investors interpret the use of non-GAAP measures?

Investors should view non-GAAP measures as supplementary information to GAAP financial results. While they can offer insights into ongoing operational performance, they should not be used as a replacement for GAAP measures. It's recommended to analyze both to gain a comprehensive understanding of Abbott's financial condition.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) has filed an 8-K report on April 16, 2025, announcing its first-quarter 2025 financial results. The filing primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott utilizes non-GAAP financial measures to present its performance, adjusting for items such as acquisition-related expenses, restructuring costs, contingent consideration adjustments, impairment charges, certain regulatory costs, tax benefits/expenses, and intangible amortization. The company states that these non-GAAP measures are intended to provide greater visibility into ongoing business performance and are used internally by management, but investors are cautioned to consider these in conjunction with, not as a substitute for, GAAP measures.

Key Highlights

1Abbott Laboratories announced its first-quarter 2025 financial results on April 16, 2025.
2The results are detailed in a press release furnished as Exhibit 99.1.
3The company will be presenting financial performance using non-GAAP financial measures.
4Non-GAAP measures exclude specified items such as acquisition expenses, restructuring costs, and contingent consideration.
5Intangible amortization expense is also excluded in the non-GAAP reporting.
6Abbott's management believes non-GAAP measures offer better insight into ongoing business operations.
7Investors are advised to consider both GAAP and non-GAAP financial measures.

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 16, 2025)

Summary

Key Highlights

Frequently Asked Questions